findmyKOL
Clinical trialNCT02229864CompletedInterventional

Pharmacokinetics of Everolimus in Absorb BVS in Patients With Coronary Artery Lesions

SponsorAbbott Medical DevicesEnrollment12Coronary Artery DiseaseCoronary Artery StenosisCoronary DiseaseCoronary Stenosis
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The ABSORB III PK sub-study is a prospective, open-label, non-blinded study enrolling approximately 12 subjects in up to 5 US sites. ABSORB III PK sub-study is a part of ABSORB III RCT (NCT01751906). The objective is to determine the pharmacokinetics of everolimus delivered by the Absorb BVS in a separate and non-randomized cohort of subjects who only receive Absorb BVS with a maximum of two de novo native coronary artery lesions after implantation of the Absorb BVS. Note: The ABSORB III PK subjects will not contribute to the determination of the ABSORB III RCT primary endpoint.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • David G. Rizik, MD

    Scottsdale Healthcare, Scottsdale, AZ

    Principal Investigator
    clinicaltrials.gov ↗
  • Louis A. Cannon, MD

    Cardiac and Vascular Research Center of Northern Michigan Petoskey, MI

    Principal Investigator
    clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Scottsdale Healthcare

    Scottsdale, Arizona, United States

  • Cardiac & Vascular Research Center of Northern Michigan

    Petoskey, Michigan, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 May 2014
Primary completion
31 Oct 2014
Completion
1 Oct 2019
Last update posted
12 Mar 2021
Registered enrollment
12
Registry id
NCT02229864
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.